You are here

  • Home
  • Archive
  • Volume 66, Issue 5
  • Lung function decline in relation to mould and dampness in the home: the longitudinal European Community Respiratory Health Survey ECRHS II

Article Text

Article menu
Download PDFPDF
Environmental exposure
Original article
Lung function decline in relation to mould and dampness in the home: the longitudinal European Community Respiratory Health Survey ECRHS II
  1. Dan Norbäck1,
  2. Jan-Paul Zock2,3,4,
  3. Estel Plana2,3,4,
  4. Joachim Heinrich5,
  5. Cecilie Svanes6,
  6. Jordi Sunyer2,3,4,7,
  7. Nino Künzli2,8,
  8. Simona Villani9,
  9. Mario Olivieri10,
  10. Argo Soon11,12,
  11. Deborah Jarvis13
  1. 1Uppsala University, Department of Medical Sciences, Uppsala, Sweden
  2. 2Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
  3. 3Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain
  4. 4CIBER Epidemiologia y Salud Publica (CIBERESP), Spain
  5. 5Helmholtz Zentrum München, German Research Centre for Environmental Health, Institute of Epidemiology, Neuherberg, Germany
  6. 6University of Bergen, Department of Thoracic Medicine, Bergen, Norway
  7. 7Department of Experimental and Health Sciences, Pompeu Fabra University (UFP), Barcelona, Spain
  8. 8Tropical and Public Health Institute (Swiss TPH), Department of Epidemiology and Public Health, Basel, Switzerland
  9. 9University of Pavia, Department of Health Science, Pavia, Italy
  10. 10University Hospital of Verona, Occupational Medicine, Verona, Italy
  11. 11University of Tartu, Department of Public Health, Tartu, Estonia
  12. 12Research and Cooperation Centre, Archimedes Foundation, Tartu, Estonia
  13. 13Respiratory Epidemiology and Public Health Group, National Heart and Lung Institute, Imperial College, London, UK
  1. Correspondence to Dan Norback, Department of Medical Science, Uppsala University and Occupational and Environmental Medicine, University Hospital, SE-751 85 Uppsala, Sweden; dan.norback{at}medsci.uu.se

Abstract

Background There are few longitudinal studies that have examined the association of lung function decline with indoor mould and dampness. Lung function decline in relation to dampness and mould in the home has studied in adults over a 9 year period.

Methods Spirometry was performed twice in participants in the European Respiratory Health Survey (ECRHS I and II) who were initially examined aged 20–45 years, in 1990–1995 and 9 years later (n=6443). Information on their current home was collected twice by interview. Dampness (water damage or damp spots) and indoor mould, ever and in the last 12 months, were assessed. A dampness score and a mould score were calculated. In addition, 3118 homes at 22 centres were inspected directly at follow-up for the presence of dampness and mould.

Results Dampness and mould were common. Overall, 50.1% reported any dampness and 41.3% any indoor mould in either ECRHS I or ECRHS II. Women with dampness at home had an additional decline in forced expiratory volume in 1 s (FEV1) of −2.25 ml/year (95% CI −4.25 to −0.25), with a significant trend in increased lung function decline in relation to the dampness score (p=0.03). The association in women was significant when excluding those with asthma at baseline. Observed damp spots in the bedroom was associated with a significant additional decline in FEV1 of −7.43 ml/year (95% CI −13.11 to 1.74) in women.

Conclusion Dampness and indoor mould growth is common in dwellings, and the presence of damp is a risk factor for lung function decline, especially in women.

  • Building dampness
  • dwelling
  • indoor environment
  • lung function decline
  • moulds
  • clinical epidemiology
  • COPD epidemiology

https://doi.org/10.1136/thx.2010.146613

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding The coordination of ECRHS II was supported by the European Commission, as part of their Quality of Life programme. The following bodies funded the local studies in ECRHS II included in this paper: Albacete: Fondo de Investigaciones Santarias (FIS) (grant code: 97/0035-01, 99/0034-01 and 99/0034-02), Hospital Universitario de Albacete, Consejeria de Sanidad; Antwerp: FWO (Fund for Scientific Research)-Flanders Belgium (grant code: G.0402.00), University of Antwerp, Flemish Health Ministry; Barcelona: SEPAR, Public Health Service (grant code: R01 HL62633-01), Fondo de Investigaciones Santarias (FIS) (grant code: 97/0035-01, 99/0034-01 and 99/0034-02) CIRIT (grant code: 1999SGR 00241) ‘Instituto de Salud Carlos III’ Red de Centros RCESP, C03/09 and Red RESPIRA, C03/011; Basel: Swiss National Science Foundation, Swiss Federal Office for Education & Science, Swiss National Accident Insurance Fund (SUVA); Bergen: Norwegian Research Council, Norwegian Asthma & Allergy Association (NAAF), Glaxo Wellcome AS, Norway Research Fund; Bordeaux: Institut Pneumologique d'Aquitaine; Erfurt: GSF-National Research Centre for Environment & Health, Deutsche Forschungsgemeinschaft (DFG) (grant code FR 1526/1-1); Galdakao: Basque Health Department; Goteborg: Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences & Allergy Research, Swedish Asthma & Allergy Foundation, Swedish Cancer & Allergy Foundation; Grenoble: Programme Hospitalier de Recherche Clinique-DRC de Grenoble 2000 no. 2610, Ministry of Health, Direction de la Recherche Clinique, Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante, CHU de Grenoble, Comite des Maladies Respiratoires de l'Isere; Hamburg: GSF-National Reasearch Centre for Environment & Health, Deutsche Forschungsgemeinschaft (DFG) (grant code MA 711/4-1); Ipswich and Norwich: Asthma UK (formerly known as National Asthma Campaign) (UK); Huelva: Fondo de Investigaciones Santarias (FIS) (grant code: 97/0035-01, 99/0034-01 and 99/0034-02); Montpellier: Programme Hospitalier de Recherche Clinique-DRC de Grenoble 2000 no. 2610, Ministry of Health, Direction de la Recherche Clinique, CHU de Grenoble, Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante, Aventis (France), Direction Régionale des Affaires Sanitaires et Sociales Languedoc-Roussillon; Oviedo: Fondo de Investigaciones Santarias (FIS) (grant code: 97/0035-01, 99/0034-01 and 99/0034-02); Paris: Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante, UCB-Pharma (France), Aventis (France), Glaxo France, Programme Hospitalier de Recherche Clinique-DRC de Grenoble 2000 no. 2610, Ministry of Health, Direction de la Recherche Clinique, CHU de Grenoble; Pavia: Glaxo-SmithKline Italy, Italian Ministry of University and Scientific and Technological Research (MURST), Local University Funding for research 1998 and 1999 (Pavia, Italy); Portland: American Lung Association of Oregon, Northwest Health Foundation, Collins Foundation, Merck Pharmaceutical; Reykjavik: Icelandic Research Council, Icelandic University Hospital Fund; Tartu: Estonian Science Foundation; Turin: ASL 4 Regione Piemonte (Italy), AO CTO/ICORMA Regione Piemonte (Italy), Ministero dell'Università e della Ricerca Scientifica (Italy), Glaxo Wellcome spa (Verona, Italy); Umeå: Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences & Allergy Research, Swedish Asthma & Allergy Foundation, Swedish Cancer & Allergy Foundation; Uppsala: Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences & Allergy Research, Swedish Asthma & Allergy Foundation, Swedish Cancer & Allergy Foundation.

    • Competing interests None.

    • Patient consent Obtained.

    • Ethics approval This study was conducted with the approval of the appropriate body at each participating centre.

    • Provenance and peer review Not commissioned; externally peer reviewed.